The KRAS‐driven activation of the MAPK pathway (MEK1/2‒ERK1/2) is a hallmark of KRAS‐mutant cancers60, 61; however, robust synergistic effects between MEKi and G12Ci have been observed only in specific subsets KRASG12C‐mutant lung cancer.8, 62, 63. The gene discussed is KRAS; the disease is lung carcinoma.